Alimera Sciences to Present at the 20th Annual HC Wainwright Global Investment Conference

Loading...
Loading...

Alimera Sciences to Present at the 20th Annual HC Wainwright Global Investment Conference

PR Newswire

ATLANTA, Aug. 29, 2018 /PRNewswire/ -- Alimera Sciences ALIM, a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, Chief Executive Officer, will be presenting at the annual HC Wainwright Global Investment Conference taking place September 5-6, 2018 at the St. Regis in New York, New York.

(PRNewsfoto/Alimera Sciences, Inc.)

The Company's presentation will take place on Thursday, September 6th at 3:00PM Eastern Time, a webcast and audio replay will be available for 90 days online at www.alimerasciences.com.

About Alimera Sciences, Inc.
www.alimerasciences.com  
Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in Alimera's product portfolio. For more information, please visit www.alimerasciences.com.

For press inquiries:

For investor inquiries:

Katie Brazel

CG Capital

for Alimera Sciences 

for Alimera Sciences

404-317-8361

877-889-1972

kbrazel@bellsouth.net

investorrelations@cg.capital

 

View original content with multimedia:http://www.prnewswire.com/news-releases/alimera-sciences-to-present-at-the-20th-annual-hc-wainwright-global-investment-conference-300703217.html

SOURCE Alimera Sciences, Inc.

Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...